Abbott Laboratories, 482
AbbVie, 213–14, 482
Abele, John, 175
Abelson virus, 344–45, 355
Abelson, Herb, 342, 344
Abgenix, 365
accelerated approval status
FDA designation, 22
ACE inhibitors
captopril (Capoten), 126, 140
captopril (Capoten), approval of, 155
enalapril, 155
enalaprilat, 155
general, 119, 135
lisinopril, 155
Monopril, 285
perindopril, 155
ramipril, 126, 155
Aecmoglu, Daron, 55
acquired immune deficiency syndrome
(AIDS), 55, 203
research on, 12
Acthar, 65n, 7
acute lymphoblastic leukemia (ALL), 419
adenylate kinase, 291
Advanced Cardiovascular Systems (ACS), 187
age-related macular degeneration (AMD), 377,
380–81, 401, 403
Aggertal Clinic, Engelskirchen, 172, 181
agricultural firms
Monsanto, 8, 482
Al-Azkhora (The Therapy), 127
Albert Einstein College of Medicine
(AECM), 83
Albers, Alfred, 92
aldosterone, 121
Allen, Duff, 165
Alliance for Cancer Gene Therapy
(ACGT), 447
Alt, Fred, 365, 386
Alzheimer, Alois, 227, 229, 242
Alzheimer’s Association, 230
Alzheimer’s disease, 55, 364, 503, 518
amyloid plaques, 228
cause, 51
contrasted with dementia, dementia with
Lewy bodies, 223
drugs under development, 245
ey early drug development, 230
ey early prediction, 251
ey early-onset, 232
general, 223
inflammatory therapies, 246
link with Down syndrome, 232
sporadic, 234
statistics, US, 224
tau hypothesis, 242, 245
American Board of Medical Specialties, 305
American College of Medical Genetics (now
American College of Medical Genetics
and Genomics (ACMG), 305
American College of Medical Genetics and
Genomics (ACMG), 305
American Heart Association (AHA), 75, 175
American Home Products, 482
American Philosophical Society, 455
American Research and Development
Corporation, 482
American Society for Hypertension
Robert Tigerstedt Distinguished Scientist
Award, 130
American Society of Clinical Oncology, 379
American Society of Hematology (ASH), 439
Amgen, 368–69, 371–72, 377, 393, 465, 482
AMP-activated protein kinase (AMPK), 289–92, 298
Amylin Pharmaceuticals, 486
amyloid cascade hypothesis, 235, 235n. 33, 237f. 8.1, 244–45, 245n. 62
amyloid precursor protein (APP), 232
amyotrophic lateral sclerosis (ALS), Lou Gehrig’s disease, 55, 364
cause, 51
Anadys Pharmaceuticals, 208
anaphylactic shock, 137
Anatomical Therapeutical Chemical (ATC) Classification System code
World Health Organization, 22
Anderson, Robert, 278
Angell, Marcia, 13, 497
Angiologische Klinik – Max Ratschow Klinik, Darmstadt, 171
angiotensin
angiotensin I and II, 121
angiotensin converting enzyme, ACE, 121
angiotensin II
use of saline instead of water, 135
angiotonin, 134
angiotonin-activator, 134
Ann Arbor, Michigan, 102
Anthem, 215
antibiotics, 18
anti-depressants
pricing, 63
antidiuretic hormone, ADH (vasopressin), 122f. 5.1
antihypertensives, 231
Aceon, 125t. 5.1
Altace, 125t. 5.1
Bumex, 125t. 5.1
Calan SR, 125t. 5.1
Capoten, 125t. 5.1
Cardizem, 125t. 5.1
Corgard, 125t. 5.1
Diuril, 125t. 5.1
Esidrix, 125t. 5.1
Indera, 125t. 5.1
Lasix, 125t. 5.1
Lopressor, 125t. 5.1
Lotensin, 125t. 5.1
Lotrel, 125t. 5.1
Lozol, 125t. 5.1
Mavik, 125t. 5.1
Midamar, 125t. 5.1
Norvasc, 125t. 5.1
Prinivil, 125t. 5.1
Procardia, 125t. 5.1
Sectral, 125t. 5.1
Tenormin, 125t. 5.1
Thallitone, 125t. 5.1
Toprol XL, 125t. 5.1
Vasotec, 125t. 5.1
Visken, 125t. 5.1
APOE4, 233, 237f. 8.1, 239
Apple, 463
Arclyst, 375
Aricept, 231
Aron Laboratories, 280
Arrhenius, C.J., 149
Arthur, Brian, 520
Aspergillus terreus, 92
AstraZeneca, 482
Paludrine, 278
atherosclerosis, 77
initiation and progression, 77
Atomic Energy Commission, US, 520
atorvastatin, 155
Auguste D
Alzheimer’s patient, 227
autoimmune diseases
drug pricing, 63
Avastin
angiogenesis, 399
compared with Lucentis, 405
general, 398
mechanism of action, 402
Aventis, 379
bacteria
discovery of, 2
Baikie, A.G., 337
Bain & Company, 394
Bakhle, Y.S. (Mick), 137
balloon angioplasty
description, 160
Baltimore, David, 341, 345–46
Banting, Frederick, 275, 516
Barber, Bernard, 520
Bateson, William, 304
Baumert, Thomas, 217
Baxter, 482, 487
Baycol, 107
Bayer, 107, 369, 381, 394
Bayh/Dole Act, 1980, 11, 54
<table>
<thead>
<tr>
<th>Index</th>
<th>529</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCR-ABL gene fusion, 333, 344</td>
<td>Kinetix Pharmaceuticals, 352</td>
</tr>
<tr>
<td>Bcr-Abl protein kinase, 346f. 11.2</td>
<td>Kite Pharma, 433</td>
</tr>
<tr>
<td>Beck, Claude, 165</td>
<td>Life Technologies, 486</td>
</tr>
<tr>
<td>Beechams Pharmaceuticals, 90, 109</td>
<td>Medarex, 365</td>
</tr>
<tr>
<td>Bell Laboratories, 463, 465, 523</td>
<td>mergers and acquisitions, 467</td>
</tr>
<tr>
<td>Bell, James, 283</td>
<td>Regeneron, 463</td>
</tr>
<tr>
<td>Bennett, John Hughes, 334</td>
<td>Regeneron, Arcayl, 375</td>
</tr>
<tr>
<td>Bergman, Per, 129</td>
<td>Regeneron, Eylea, 375</td>
</tr>
<tr>
<td>Berman, Leonard, 147</td>
<td>Regeneron, Lucentis, 380</td>
</tr>
<tr>
<td>Best, Charles, 275, 517</td>
<td>Regeneron, name origin, 374</td>
</tr>
<tr>
<td>beta blockers, 125</td>
<td>Regeneron, Orphan Receptor initiative, 374</td>
</tr>
<tr>
<td>Bethesda Naval Hospital, 119</td>
<td>Regeneron, Praluent, 387</td>
</tr>
<tr>
<td>bevacizumab, 398</td>
<td>Regeneron, Regeneron 5, 392</td>
</tr>
<tr>
<td>Beyond the Shadow of a Drought report, 19</td>
<td>Regeneron, Taxotere, 379</td>
</tr>
<tr>
<td>Big Ag, 8, 451</td>
<td>Regeneron, TRAP technology, 375</td>
</tr>
<tr>
<td>Big Pharma, 5, 8–9, 362, 381, 451</td>
<td>Regeneron, VelociGene technology, 368, 382</td>
</tr>
<tr>
<td>big-C scientific creativity definition, 457</td>
<td>Regeneron, VelociSuite technologies, 384</td>
</tr>
<tr>
<td>Bilheimer, David, 95</td>
<td>resilience as a factor of success, 362</td>
</tr>
<tr>
<td>Biogen, 252, 260, 393–94, 477, 482, 484, 487</td>
<td>technological innovations, 467</td>
</tr>
<tr>
<td>biologics, 7, 21, 25, 29, 54</td>
<td>Vertex, 205</td>
</tr>
<tr>
<td>Biologics License Applications (BLAs) definition, 21</td>
<td>biotechnology companies, mergers and acquisitions, 500</td>
</tr>
<tr>
<td>biotech, 7</td>
<td>biproduct inhibitor, vii</td>
</tr>
<tr>
<td>small, 9</td>
<td>Birndorf, Howard, 487</td>
</tr>
<tr>
<td>biotechnology companies Abgenix, 365</td>
<td>Bishop, Michael, 343</td>
</tr>
<tr>
<td>Amgen, 368–69, 371–72, 377, 393, 465</td>
<td>Black, Donald, 104</td>
</tr>
<tr>
<td>Baxter, 482, 487</td>
<td>Blair, Henry, 477</td>
</tr>
<tr>
<td>Biogen, 260, 393–94, 477, 482, 484, 487</td>
<td>Bloch, Konrad, 83</td>
</tr>
<tr>
<td>Biogen, Alzheimer's drug research, 252</td>
<td>blood pressure drugs pricing, 63</td>
</tr>
<tr>
<td>Celera Genomics, 329, 524</td>
<td>Blumberg, Baruch</td>
</tr>
<tr>
<td>Chiron Corporation, 193, 198, 218</td>
<td>hepatitis B screening test, 193</td>
</tr>
<tr>
<td>fully integrated biopharmaceutical companies (FIBCOs), 362</td>
<td>Bock, Lazlo, 111</td>
</tr>
<tr>
<td>Gen-Probe, 487</td>
<td>Bodmer, Walter, 345</td>
</tr>
<tr>
<td>Genentech, 368, 378–79, 381–82, 391, 395, 403, 405</td>
<td>Bohr Model, 53</td>
</tr>
<tr>
<td>Genentech University, 405</td>
<td>Bohr, Niels, 53, 327</td>
</tr>
<tr>
<td>Genentech, Herceptin, 403</td>
<td>Bokelman, Delwin, 111</td>
</tr>
<tr>
<td>Genzyme, 477, 482</td>
<td>Boston Consulting Group, 481</td>
</tr>
<tr>
<td>geographic clusters, 477</td>
<td>Boston, Massachusetts, 85</td>
</tr>
<tr>
<td>Hybritech, 487</td>
<td>Boveri, Theodor, 335</td>
</tr>
<tr>
<td>Illumina, 486</td>
<td>Boyer, Herbert, 477</td>
</tr>
<tr>
<td>Inhibitex, 208</td>
<td>Bradley, Daniel W., 193</td>
</tr>
<tr>
<td>Intermune, Infergen, 203</td>
<td>bradykinin, 136</td>
</tr>
<tr>
<td>Juno Therapeutics, 433</td>
<td>bradykinin potentiating factors (BPFs), 137</td>
</tr>
<tr>
<td></td>
<td>Braun-Menéndez, Eduardo</td>
</tr>
<tr>
<td></td>
<td>renin, 132</td>
</tr>
<tr>
<td></td>
<td>breakthrough drug status FDA definition, 22</td>
</tr>
<tr>
<td></td>
<td>breast cancer hereditary, 326</td>
</tr>
</tbody>
</table>
Index

Brentjens, Renier, 424, 436, 446
Brierley, J.B., 229
Bright, Richard, 127, 146
Bristol-Myers Squibb (BMS), 103, 106, 208, 213, 215, 219, 285
Squibb Institute for Medical Research, 138
British National Formulary, 281
Brookhaven National Laboratory, 138
Brown, Michael, 95–98, 113–14, 364
Brown-Séquard, Charles Edouard, 128
Bruenn, Howard, 119
Buchdunger, Elizabeth, 349, 355
buformin, 263f. 9.1, 270t. 9.1, 282–83, 294
Bumpus, Merlin, 135
Burn, J. Harold, 151
Bush, George W., 54
Byers, Larry, 142

California Institute for Regenerative Medicine, 486
Cambridge Innovation Center, 484
Cambridge, Massachusetts biotech cluster, 481
Campana, Dario, 429
Canaani, Eli, 345
Canadian Diabetic Association (CDA), 283
cancer, 1
chemotherapy, 18
mortality, 18
Philadelphia chromosome-positive chronic myelogenous leukemia, 63
treatment overview, 418
US statistics, 441
Cancer Research Institute, 404
Cape Province, South Africa, 104
captopril
ACE inhibitor, 126, 140
captopril, ACE inhibitor approval of, 155
CAR T-cell therapy, 417
CAR T-cells
manufacture and administration, 424
carboxypeptidase A, 142
cardiovascular disease (CVD)
development of statins, 75
role of cholesterol, 79
root cause, atherosclerosis, 77
Case Western Reserve University, 131
Caspersson, Torbjörn, 339
Celera Genomics, 329, 524
Centers for Disease Control & Prevention, US (CDC), 193, 198
Chain, Ernst Boris, 16

double serendipity, 338
Horace Walpole, 458
role in scientific discovery, 152
Chaveau, Jean-Baptiste Auguste
double lumen catheter, 164
Chemical Development, 102
Chen, K.K., 278
Children's Hospital of Philadelphia, 417, 432
chimeric antigen receptor (CARs), 417
Chiron Corporation, 193, 198, 218
cholesterol
biosynthetic pathway, 86, 117
end-product inhibition, 85
HM-G-CoA reductase, 86
role in cardiovascular disease, 79
chronic lymphocytic leukemia (CLL), 419
use of CAR-T therapy, 417
chronic myelogenous (or myeloid) leukemia (CML)
description, 331
use of imatinib in treatment, 311
use of imatinib, 316
Chung, Raymond, 217
Ciba-Geigy, 284, 333, 347, 349–52, 355, 357, 359
Ciba-Geigy, protein kinase inhibitors, 347
CIBE, 92
Cleveland Clinic, 135, 167–68
Cohen, Barry
Merck, 94
Cohen, Stanley, 477
Collett, Marc, 344
Collins, Francis, 250
Collip, James Bertram, 275
Columbia University, 365
Community Health Initiative, 319
Conquest of Cancer Act, 340, 356–57
consumers’ surplus, economic term, 48
Cook Group, 186
Cook, William
The Cook Company, 169
Copernicus, 518
Cordes, Eugene, 111
Cornell University, 364
coronary artery bypass with graft (CABG) surgery, 161
coronary artery heart disease, 120
Corsellis J.A.N., 229
creative people
personality traits, 453
Index 531

Cresswell, Ronnie
Parke-Davis Research, 103
Creutzfeldt-Jakob (mad cow) disease, 223
Cri du Chat syndrome, 337
crizotinib, 312
Cruzan, Susan M., 284
Card, E.H.S., 277
CURVES study, 106
Cushman, David, 139, 152
Caster, Philip, 338
Cutler, Elliott, 165
CVS, 215
cycloc AMP (cAMP), 292
cystic fibrosis, 68
cytokine interleukin-1 (IL-1), viii, 246, 375, 378f. 12.1
cytokine storm, 431
Czechoslovak Radiologic Congress, 170
Daichi Sankyo, 82
Daklinza, 215
Daley, George Q., 346
Dallas, TX, 95–96
Dana-Farber Cancer Institute, 347, 350
Darwin, Charles, 457
Davis, Jefferson, 474
Davis, Sam, 375
de Geus, Arie, 474
De Humanis Corporis Fabrica, 14
Dechiara, Tom, 366
Department of Agriculture, US, 481
Department of Energy, US, 481
Department of National Health and Welfare, Canada, 283
Department of Veterens Affairs, US, 213
diabetes, 18
cause, 52
diabetes, type 2
cmpared with diabetes, type 1, 264
discovery of insulin, 275
drugs, history, sulfonylureas, 268
metformin, 262
statistics, 266
Synthalin, 274
Digital Equipment, 482
diguanides, ix, 263f. 9.1, 269f. 9.1, 279, 294
direct acting antivirals (DAAs)
boceprevir (Victrelis), 205
overview, 205
teleprevir (Incivek), 205
Discovery Chemistry, 102
discovery hubs
Asia, 522
discovery in the life sciences
economic model, 5
effect of price discrimination, 402
funding decisions, 43
high costs of R&D, 491
improvements in agriculture and health, 2
late 1990's changes, 11
management issues, 449
organizational form and influence, 5
role of government, 491
role of the team/group, 461
role of unintentional findings, 460
summary of history, 14
theories and ideas about, 5
theories for falloff in new discoveries, 10
theories of causes, 519
Dotter, Charles, 161, 168
Dotterization, Dottering, 170
double helix, 55
Down syndrome, 337
cause, 308
Down, John Langdon, 305
Drachman, David, 230
Drucker, Brian, 347, 350, 359
drug development, new
average cost calculation, 31
cost estimates - cash versus capitalized, 32
costs, 29
economic theories, 52
history, 19
history, 1990s, 53
tax benefits, 33
drug prices
not related to R&D costs, 30
drug pricing
price discrimination, 402
Duckworth, Angela
concept of "Grit", 361
Duplumbab, 387
Duval, Denise, 280
Eastman Kodak, 167
Ebola virus, 195, 387
Economidou, Aris, 375
Einstein, Albert, 457
Elan Pharmaceuticals, 240
Eli Lilly, 187, 238, 251, 486
Eli Lilly & Company Biological Laboratories, 276
Eli Lilly Research Laboratories, 132
Emanuel, Ezekiel, 498
Emory University, 187
Emperor Charles II, 14
enalapril, ACE inhibitor, 155
enalaprilat, ACE inhibitor, 155
Endo, Akira, 75, 115, 396
Compactin Development Project, 1976, 89
history, 82
Lasker –DeBakey Clinical Medical Research Award, 2008, 85
Erikson, Ray, 344
Erom’s Law, 19
Eshhar, Zelig, 426, 446
European Medical Agency (EMA), 441
exome sequences, 319–20
Express Scripts, 215
Eylea, 362, 375
Fagan, Violet M., 84
familial hypercholesterolemia (FH), 323
Fandl, Jim, 366
Farbwerke Hoechst, 276
Fasciolo, Juan
renin, 132
fast track approval, 104
Favaloro, Renee
first coronary artery bypass with graft (CABG), 168
Feldberg, Wilhelm, 137
Ferrara, Napoleone, 404, 415
Ferreira, Sergio, 137
financing discovery
economic model, 6
introduction to issues, 6
first in class drugs
ATC category, 22, 25, 28
Fleming, Alexander, 75, 179
connection to Akira Endo’s work, 86
discovery of penicillin, 512
discovery of penicillin. See penicillin
Flemming, Walther, 335
Florey, Howard Walter, 16
Fogarty, Thomas, 171
Food and Drug Administration (FDA), US, 207, 387, 409, 433, 441
accelerated approval status, 22
Alzheimer’s treatments, 253
Avastin, 398
biologics license applications (BLAs), 362
biotech firms, NCEs and NBEs, 466
breakthrough drug designation, 22
drug approval methods, 11
drug review designations, 22
fast track approval, 104
lack of attention to profits, 493
Orphan Drug Act, 24
Orphan drug designation, 22, 29, 33
Poisonous Plant Database, 298
policies, 46
Priority Review status, 22
Safety and Innovation Act (FDASIA), 209
Forssman, Werner, 165
Fortune magazine, 106
Fovea Pharmaceuticals, 380
Fox Chase Cancer Center, Philadelphia, 338
Framingham Heart Study, 85, 113, 117
Framingham, Massachusetts, 85
Frank, Erich, 273
Fred Hutchinson Cancer Research Center, Seattle, 433
French Academy of Sciences, 511
fronotemporal dementia, 223–24, 243f. 8.2, 246
G7 countries
NME approvals, 29
galegine, 269t. 9.1
Galen, 14, 505
Garcia, Eusebio, 278
Garrod, Sir Archibald
Cronian Lectures, 305
gastrointestinal stromal tumor (GIST), 312
Gattex, 66
Geisinger, 329, 392
Geisinger GenomeFIRST™, 412f. 10.4
Geisinger Health System (GHS), 317
Genentech, 368, 378–79, 381–82, 391, 393, 395, 402–03, 405
Herceptin, 403
Genentech University, 405
General Practice Research Database, UK, 126
generic drugs
investment in, 51
new, 21
genetic revolution, 55
genetics
definition, 301
genomic medicine
GenomeFIRST™ approach, 320
Phenome First approach, 306
value of, 315
genomics
definition, 301
Gen-Probe, 487
Genzyme, 477, 482
Gianturco, Cesar, 187
Gilbert, Walter, 477
Index

Gilead, 208, 213, 220
Gilman, Alfred, 364, 369
Glasgow Blood Pressure Clinic, 126
GlaxoSmithKline, 64, 90, 469
Centers of Excellence for Drug Discovery (CEDD), 495
Gleevec (imatinib), 418
2-phenylaminopyrimidine, 349
introduction, 331
glucagon, 289f. 9.4, 290f. 9.5, 292
gluconeogenesis inhibition, 268, 286, 291, 293
Goat's rue, Galega officinalis, 270
Goldberg, Murray, 369
Goldblatt, Harry, 135, 147
kidney clamp, 131
Goldstein, Jim, 114
Goldstein, Joseph, 95–98, 113, 364
Golgi, Camillo, 228
Google, 111
Grant, Ulysses, 475
Grundy, Scott, 95
Guidant Corporation, 187
Guy's Hospital, 127
Guys Hospital Report, 128
HAART (highly active anti-viral therapy), 206
Hagedorn, Hans Christian, 276
hairy cell leukemia, 203
Hales, Stephen, 164
Hanna, Elias, 176
Hansemann-Boveri hypothesis, 335
Hardy, John, 235
Harvard University, 426, 477–78, 485
Harvey, William, 127, 516
Hassell, H.M.
opposition to use of catheters, 172
HCV infectious cycle, 196
HCV drug development
timeline, 207
HCV genome organization, 195
Healthcare Common Procedure Coding System (HCPCS), 380
heart disease, 1
cardiac catheterization, 163
types of medical devices, 163
heart failure, 120
Heart Protection Study (HPS), UK, 113
hepatitis A virus (HAV) compared to HBV and HCV, 193
hepatitis B virus (HBV) compared to hepatitis C virus (HCV), 193
hepatitis C
drug pricing, 63
Sovaldi, 58
hepatitis C virus (HCV), 187
Daklinza, 213, 215
direct acting antivirals (DAAs), 205
drug discoveries, 204
drug pricing, 211
Epclusa, 213
growth in drug sales, 207
ledipasvir (Harvoni), 211
lost productivity, US workforce, 192
Olysio, 213
sofosbuvir (Sovaldi), 209
Viekira Pak, 213–14
Viekira XR, 213
worldwide infection statistics, 191
Zepatier, 213, 215
Herceptin, 403
heterozygous familial hypercholesterolemia (FH), 90
Higgins, Gerald, 235
high blood pressure
drug development, 57
high cholesterol
drug development, 57
high density lipoproteins, HDLs, 81
Himsworth, Harold, 266
Hippocrates, 127, 302, 304
Hitotsubashi University, Japan
Institute of Innovation Research, 459
HMG-CoA reductase, 86
Hoechst AG, 482
Holland, Michigan, 102
Hollunger, Gunnar, 287
Hooke, Robert, 516
Hopf, Heinrich, 173
Hôpital de la Pitie, Paris, 280
Horecker, Bernard, 109
534

Index

Horovitz, Zola, 141
Houghton, Michael, 193
Houssay, Bernardo A.
renin, 132
Hsu, T.C., 336
Huebner, Robert J., 343
Human Genome Project (HGP), 309, 319
human genome, mapping, 56
human papillomavirus (HPV), 203
humanized monoclonal antibodies, 405–06, 415
Hungerford, David, 334, 338
Hunger, John, 163
Hunter, Tony, 344
hybridization and selective breeding, 2
Hybritech, 487
hypercholesterolemia
Praluent, 387
hyperglycemia, 265
hypertension, 119
statistics, US, 120
Icahn School of Medicine, Mt. Sinai, 201
Icahn, Carl, 394
idea
definition of, 56
Idec Pharmaceuticals, 487
Illingworth, Roger, 95, 104
Illumina, 486
imatinib, 316
treatment for CML, 311
Imhotep
Edwin Smith Surgical Papyrus, 127
immunotherapy
drugs, Humira, Embrel, Avastin, Lucentis, 240
Imperial Chemical Industries Ltd., 277
infectious disease, 2
Institut Pasteur, 15
Institute for Clinical and Economic Review (ICER), 499
Institute of Biology, São Paulo, Brazil, 136
Institute of Medicine, 327
insulin
discovery, 275
Intel, 473
intellectual property
disputes, 13
interferons
drawbacks to treatment, 202
general, 202
interferon alpha, 202

Intermune, 203
intuitive medicine
definition, 304
investment
conceptual model of investing, 43
decision-making, 47
fundamental equation, 44
probability that product will come to market, 44
Jacobs, Patricia, 337
Jenner, Edward
Jennerian Society, 15, 509
smallpox vaccine, 508
Jobs, Steve, 455
Johnson & Johnson, 205, 213, 482, 486
Johnson, Steven, 522
Joslin, Eliot P., 276
Judkins, Melvin, 168, 170
June, Carl, 427, 436, 445
Juno Therapeutics, 433
JUPITER study, 108
Kahn, Joseph R., 135
Kalydeco, 68
Kanazawa University School of Medicine, Ishikawa, Japan, 96
Kanter, Rosabeth Moss, 449, 489
Kaposi’s sarcoma, 203
Karlový Vary (Karlsbad), 170
Karolinska Institute, 129, 167
Katzen, Robert, 230
Kayali, Zeid, 211
Kellaway, Charles Halliley, 137
Kenexa, 367
Kidd, Michael, 229
kidney disease, 120
Kinetix Pharmaceuticals, 352
King Charles I, 516
King James I, 516
Kitano, Noritoshi, 88, 109, 117
Kite Pharma, 433
Klausner, Richard, 426
Kleiner Perkins, 487
Klinefelter’s syndrome, 337
Koestler, Arthur, 457
Kornberg, Arthur, 364
Kraepelin, Emil, 227
Krogh, August, 276
Krogh, Marie, 276
Index

Kuhn, Thomas
paradigm shift, 3, 55, 517
Kuroda, Masao, 86
Kuwait, 107
kymograph
invention, 129
La Jolla Institute, 485
La Jolla, California, 95
Lacquer, Ernst, 147
Lander, Eric, 308
Landsteiner, Karl, 303
Laragh, John, 141
LDL receptors, 98n. 50
LDL receptors (LDLRs), 90, 97–98, 112, 388
Leavitt, Janet, 230
ledipasvir, 211
Lee, Tim Berners, 484
Leloir, Luis. F.
renin, 133
Lescol, 106
Leu, Hans Jorg, 174
Levan, Albert, 337
Levine, Bruce, 427
Lichtlen, Paul, 185
Life Technologies, 486
Lilly Research Laboratories, 278
Lincoln, Abraham, 474
Lindblom, Charles, 474
Linn, Joshua, 55
Lipha Pharmaceuticals Co. Ltd, 285
Lipitor (atorvastatin), 101, 155
Lipopay, 107
Lipscomb, William, 142
lisonopril, ACE inhibitor, 155
little-C creativity
definition. See big C scientific creativity
London School of Economics, 137
London, UK, 127
lovastatin, 99, 117, 155
discovery, 93
low density lipoproteins, LDLs, 79
Lucentis, 380
compared with Avastin, 405
general, 398
Lucille P. Markey Charitable Trust, 365
Ludwig, Carl, 146
Lydon, Nicholas, 355
Lynch syndrome, 320
Mabuchi, Hiroshi, 96
MacDonald, Lynn, 383
MacLeod, John, 275, 516
Macugen, 380
Malaria
treatments, Paludrine, 278
treatments, quinine, 277
Manhattan Project, 357
Martin, Daniel, 411
Martin, John, 209
Massachusetts Institute of Technology (MIT), 478
Sloan School of Management, 484
Matter, Alex, 347, 355
Max Planck Institute of Biochemistry, Martinsried, Germany, 406
Maximillian, Holy Roman Emperor, 506
McDonald, Jim, 111
McIntire, Ross T., 119
MD Anderson Cancer Center, University of Texas, 532
me-too drugs
investment in, 51
new, 21
Medarex, 365
Medawar, Peter, 451
medical device companies
Advanced Cardiovascular Systems (ACS), 187
Boston Scientific, 175
Cook Group, 186
Guidant Corporation, 187
Medi-Tech, 175
William Cook Europe, 178
medical devices
innovation, 160
medical genomics
definition, 301
Mehnert, Helmut, 282
Memorial Sloan Kettering Cancer Center, 429, 432–33
Mendel, Gregor
Mendelian disorders, 302
Merck & Co., 91, 115, 130, 155, 205, 213, 215, 373, 396, 452, 486, 513
Woodruff, H. Boyd, 91
mergers and acquisitions
efforts to achieve economies of scale, size
efficiency, 9
Merrill Lynch Ventures, 369
metformin
effects on metabolism, 287
Mevacor (lovastatin), 93, 98, 103, 106, 155
mevalonate, 86
mevastatin, 87
Mexico City, 521
Meyer, Thomas, 349
Milken Institute, 484
Milligan, John, 209
Milne, J.S., 337
Minkowski, Oscar, 274
Moloney virus, 344
Monascus ruber, 93
Monsanto, 8, 482, 520
Moore, Gordon, 473
Morgan, Thomas Hunt, 336
Mukherjee, Siddartha, 300, 405
Müller, Helmut, 273
Munich, Germany, 228
Muñoz, Juan M., 133
Murphy, Drew, 367, 382
MyCode® bio-repository (now Community Health Initiative), 319
Myler, Richard, 175, 177
Nash, John, 453
National Academy of Sciences, 455
National Alzheimer’s Project Act (NAPA), 255
National Cancer Act of 1971, 340, 357, See War on Cancer
National Cancer Institute (NCI), 341, 441
National Cardiovascular Center, Osaka, Japan, 89
National Eye Institute, 382, 410
National Heart, Lung and Blood Institute formerly National Heart Institute, 85
National Institute for Health and Clinical Excellence (NICE), UK, 297
National Institute of Allergy and Infectious Diseases, US, 193
National Institutes of Diabetes and Digestive and Kidney Diseases, US (NIDDK), 200
biomedical research funding, 18
Comparison of Age-Related Macular Degeneration Treatment Trial (CATT) trials, 410
funding for San Diego biotech cluster, 485
human genome mapping, 329
Institute of Translational Research (NCATS), 397
National Cancer Institute, 341
peer review, 29
research spending, 46
translational research, 8
National Science Foundation, US, 481
Naval Medical Research Institute, Bethesda, Maryland, 427, 445
NCATS. See National Center for Advanced and Translational Science nephropathic cystinosis, 64
neurofibrillary tangles (NFTs), 228
New Molecular Entities (NMEs) definition, 21
different types, 24
international approvals, 28
revenues, 26
New York Medical College, 154
New York, NY, 85, 106, 109
Newton, Isaac, 457
Newton, Roger, 102
Nobel Prize, 16
Howard Temin, 1966, 343
Phillip Sharp, 1993, 484
Nobel Prize in Physiology or Medicine Alfred Gilman, 1994, 364
Arthur Kornberg, 1959, 364
Banting and McLeod, insulin, 276
Joseph Goldstein and Michael Brown, 1985, 364
Nobel Prize in Physiology or Medicine, 1985, 96
Nobel Prize, 1978
nomination of Grünzig and Dotter, 178
Nordisk Insulinlaboratorium, 276
Novartis, 106, 219, 333, 352, 357, 369, 429, 486 Lucentis marketing rights, 409
Novartis-Penn Center for Advanced Cellular Therapeutics, Philadelphia, 433
Novo Terapeutisk Laboratorium (now Novo Nordisk), 276
Nowell, Peter, 334, 338, 354
Noyce, Robert, 473
NPS Pharma, 66
Obama, Barack, 54
Olson, Doug, 417, 432, 445
Ondetti, Miguel, 139
Oregon Health and Science University, 104, 350, 404, 443 organizations determining best types for innovation, 8
Orphan diseases
drug pricing, 63
treatment for, 58
Index

Orphan Drug Act, 24, 54, 494
tax credits, 33
Orphan drugs, 7
FDA designation, 22, 29, 33
Orphan Drug Act, 24, 54
Procysbi, 64
Osborn, Alex F., 462
ovarian cancer
hereditary, 326
Oxford University, 151, 521
Page, Irvine, 147
renin, 132
Palmaz, Julio, 187
Palludrine
malaria treatment, 278
Papadopoulos, Nick, 367, 375
paradigm shift, 3, 55
definition, 457
Paris, France, 128
Parkinson's disease, 223, 248, 364
Pasteur, Louis, 508
change, 154
discovery of bacterial infection, 10
Pasteur model, 53
pasteurization, 510
Patents
protected drugs, 59
Pauling, Linus, 457
PCOS (polycystic ovary syndrome)
treatment with metformin, 295
Peart, Stanley, 135
penicillin, 75
*Penicillium citrinum*, 85
Penn AD Core Center (ADCC), 249
perindopril, ACE inhibitor, 155
peripheral vascular disease, 120
personalized medicine
definition, 302
Regeneron Genetics Center (RGC), 392
Pfizer, 8, 67, 105, 117, 469, 482, 486
Pharmaceutical companies
Abbott Laboratories, 482
AbbVie, 213, 482
Abbvie, Viekira Pak, 214
American Home Products, 482
Amgen, 482
Amylin Pharmaceuticals, 486
Anadys Pharmaceuticals, 208
Aron Laboratories, 280
AstraZeneca, 278, 482
Aventis, 379
Bayer, 107, 369, 381, 394
Beechams, 90, 109
BMS, Daklinza, 215
Bristol Myers, 106
Bristol-Myers Squibb, 103, 208, 213, 219, 285
Bristol-Myers-Squibb (BMS), Squibb
Institute for Medical Research, 138
Ciba-Geigy, 284, 333, 347, 349–52, 355, 357, 359
Ciba-Geigy, protein kinase inhibitors, 347
Daichi Sankyo, 82
Eli Lilly Pharmaceuticals, 240
Eli Lilly, 187, 238, 486
Eli Lilly & Company Biological Laboratories, Greenfield, Indiana, 276
Eli Lilly Research Laboratories, 132
Eli Lilly, Alzheimer's drug research, 251
Eli Lilly, Lilly Research Laboratories, 278
Farwerke Hoechst, 276
Fooda Pharmaceuticals, 380
Genentech, Avastin, Lucentis, 402
Gilead, 208, 213, 220
Gilead, Sovaldi, 209
GlaxoSmithKline, 64, 90
GlaxoSmithKline, biotech-like units, 469
GlaxoSmithKline, Centers of Excellence for Drug Discovery (CEDD), 495
Idec Pharmaceuticals, 487
Imperial Chemical Industries Ltd., 277
Johnson & Johnson, 205, 213, 482, 486
Kinetix Pharmaceuticals, 352
Liphia Pharmaceuticals Co. Ltd. (now owned by Merck KGAA), 285
Lovartis, 106
Lucentis marketing rights, 409
Merck, 16, 91, 115, 130, 155, 205, 213, 373, 396, 452, 486, 513
Merck, H Boyd Woodruff, 91
Merck, P. Roy Vagelos, 91
Merck, Zepatier, 215
Nordisk Insulinlaboratorium, 276
Novartis, 219, 333, 352, 357, 369, 429, 486
Novartis, Gleevec, 333
Novartis-Penn Center for Advanced Cellular Therapeutics, Philadelphia, 433
Novo Nordisk, 276
Novo Terapeutisk Laboratorium (now Novo Nordisk), 276
NPS Pharma, 66
**Index**

| Pharmaceutical companies (cont.) | Express Scripts, 215 |
| Pfizer, 8, 67, 105, 117, 482, 486 | Prime Therapeutics, 215 |
| Pharmasset, 208, 210, 219 | Pharmasset, 208, 210, 219 |
| Pfizer, purchase of Warner-Lambert, 107 | phenformin, 263, 263f. 9.1, 270t. 9.1, 282–84, 291, 294, 299 |
| Questcor, 65n. 7 | phenobarbital, 119 |
| Raptor, 64 | Philadelphia chromosome, 312, 333 |
| Regeneron, 362 | approval of Gleevec as treatment, 353 |
| Regeneron, Eylea, 362 | discovery, 334, 338 |
| Regeneron, Praluent, 363 | Philadelphia chromosome-positive chronic myelogenous leukemia (CML), 63 |
| Roche, 208, 391 | Philadelphia, PA, 115 |
| Roche, Pegasyx, 204 | Philips, 167 |
| Roche, purchase of Anadys | Pittsburgh, PA, 485 |
| Pharmaceuticals, 208 | Pfizer, 463 |
| Roche, Roferon A, 203 | polycystic ovary syndrome (PCOS), 263 |
| Rona, Aron Laboratories, 281 | Portland, Oregon, 95 |
| Sandoz Pharmaceuticals, 102, 350, 352 | Posner, Richard, 13 |
| Sandoz, fluvastatin, 110 | Praluent, 363, 387 |
| Sankyo Research Laboratories, 85 | Prasad, Vinay, 443 |
| Sanofi, 369, 379, 389, 394 | Pravachol, 103, 106 |
| Sanofi-Aventis, 276 | precision medicine, 301 |
| Schering AG, Synthalin, 274 | Precision Medicine Initiative, 314 |
| Schering-Plough, 205 | prediabetes, 263, 267, 296n. 101, 296n. 98, 295–98 |
| Schering-Plough, Intron A, 203 | treatment with metformin, 295 |
| Schering-Plough, Rebetrone, 204 | Presbyterian Hospital, Philadelphia, 338 |
| Sumitomo, 369 | Prescription Drug User Fee Act (PDUFA), 54 |
| Teva, 369 | presenilin-1, 232, 236n. 37, 236n. 38 |
| Vertex, 68 | presenilin-2, 232 |
| Warner-Lambert, 117 | pricing, pharmaceuticals, 59 |
| Warner-Lambert, Parke-Davis | elasticity, 62 |
| Pharmaceutical Research, 100 | marginal value, 60 |
| Pharmaceutical companies, mergers and | value distribution, 60 |
| acquisitions, 500 | Pricing, pharmaceuticals |
| BMS purchase of Inhibitex, 208 | Lerner Index. See pricing, pharmaceuticals: |
| Gilead purchase of Pharmasset, 208 | Markup pricing rule |
| Merck-Schering Plough, 389 | price discrimination, 61 |
| Novartis, 352 | price discrimination, EU versus US, 411 |
| Pfizer-Wyeth, 389, 469 | Prime Therapeutics, 215 |
| Sanofi, Aventis acquisition, 379 | priority review status, 22 |
| Pharmaceutical innovation | Procter & Gamble, 369, 377 |
| BLAs, 21 | Procybsi, 64 |
| definition of new drug, 21 | prozenin, 121 |
| generic drugs, 21 | Proudfit, William, 167 |
| me-too drugs, 21 | Ptolemy, 518 |
| NMEs, 21 | Purcell, Robert, 193 |
| Pharmaceutical Research | Pythium ultimum, 87 |
| and Manufacturers of America | Questcor, 65n. 7 |
| (PhRMA), 26 | Raal, Frederick, 105 |
| Annual Report, R&D spending, 34 | Rabbi Judah the Prince, 304 |
| NMEs, percent of R&D spending, 31 | pharmacy benefits management companies |
| Asphalt, 215 | Anthem, 215 |
| CVS, 215 | Express Scripts, 215 |

© in this web service Cambridge University Press

www.cambridge.org
Index

Rabstein, Louise, 344
Radiological Society of North America, 169
Rahway, New Jersey, 92
ramipril, ACE inhibitor, 155
Ramipril, ACE inhibitor, 126
RAND Corporation, 225
ranibizumab, 398
Raptor, 64
Raspaill, Francois-Vincent, 335
Rathery, Francis, 280
Reagan, Ronald
Alzheimer’s disease, 254
Regeneron, 362, 463
Arcalyst, 375
Eylea, 375
Lucentis, 380
name origin, 374
Orphan Receptor Initiative, 374
Praluent, 387
Regeneron S, 367, 392
Regeneron Genetics Center (RGC), 392
Taxotere, 379
TRAP technology, 375
VelociGene technology, 368, 382
VelociSuite technologies, 384
Zaltrap, 375
Reid, Donald, 171
Reinwein, Helmuth, 273
renin, 130
renin-angiotensin-aldosterone system
(RAAS), 121
Rensslear, New York, 381
Reports of Medical Cases, 128
research and development (R&D)
1986 tax credit system, US, 33
cost estimates - cash versus
capitalized, 32
costs, 29
expenses, US, 18
investment decision-making, 47
R&D dollars per drug, 37
rate of return, 30
return on investment (ROI), 30
revenues per R&D dollar, 37
small molecule, 25
tax benefits, 33
Rhea, Lawrence, 165
rheumatoid arthritis
cause, 52
drug development, 57
Ricardo, David, 38
Roberts, Tom, 347
Roche, 203–04, 208, 391
Rochester, NY, 100
Rockefeller University, 135, 201, 220, 342
Roosevelt, 119
Roosevelt, Franklin Delano (FDR), 119
Roth, Josef, 170
Rosenberg, Nathan, 519
Rosenberg, Steven, 428–29
Rosenfeld, Philip J., 408
Roth, Bruce, 100
Roth, Martin, 230
Rothfield, Lawrence, 83
Roubin, Gary, 187
Rous, Peyton, 342
Rowley, Janet, 339, 354
Royal College of Surgeons, London, 137
Royal Society of England, 15, 508
Royal Victoria Hospital, Belfast, 281
Royston, Ivor, 487
Rubin, Harry, 342
Rutgers University
Institute for Microbiology, 17
Sadelain, Michel, 429, 436, 446
Salk Institute for Biological Studies, 478, 485, 487
San Diego, California
biotech cluster, 484
Sandoz
fluvastatin, 110
Sandoz Pharmaceuticals, 102, 350, 352
Sanford Burnham Institute, 485
Sanger, Fred, 457
Sankyo Research Laboratories, 85
Sanofi, 369, 379, 389, 394
Sanofi-Aventis, 276
Sawyers, Charles, 352
Scandinavian Simvastatin Survival Study (the 
‘4S study’), 99
Schatz, Albert, 514
streptomycin. See streptomycin
Schering AG, 274
Schering-Kahlbaum AG, 274
Schering-Plough, 203–05
Schumpf, Maria, 173
Schmid, Helmuth, 175
Schmidt, Warren, 211
Schonberg, Georg Albers, 92
Schumpeeter, Joseph, 13
scientific method
definition, history, 163
Scolnick, Edward, 96
Scott, Winfield, 475
Scripps Research Institute, 200, 478, 485
Seattle, Washington, 433
Seed, Brian, 426
Selton, Batholomew, 344
Seitz, Walter, 282
Seldinger, Sven Ivar
Seldinger Technique, 167
Senning, Ake, 168, 177, 181
Séquard, Charles Edward Brown, 146
Sharp, Phillip
Nobel Prize, 1993, 484
Sharp, Phillip Allen, 477
Shenfield, Gillian, 262
Shirey, Earl, 167
Shleifer, Leonard (Len), 363
Shooter, Eric, 364
Siegenthaler, Walter, 181
Silva, Mauricio Rocha e, 136
Simpson, John, 187
simvastatin, 98
Sing, George, 369
Siperstein, Marvin D., 84
Skeggs, Leonard, 135, 148
Slamon, David, 406
Slater, Robert, 349
Sloan School of Management, MIT, 484
Slotta, K.H., 282
small molecule R&D, 25
Smith, Charles (Chuck), 139
Société de Biologie, 128
Sofia, Michael, 210, 219
Sones, Frank Mason, 167, 179
Sovaldi, 58, 209
specialty drugs
ATC category, 23, 25
spotlight effect
definition, scientific community, 146
St Mary Abbots Hospital, London, 281
St Mary’s Hospital Medical School, London, 135
St. Jude Children’s Research Hospital, 429
St. Mary’s Hospital, San Francisco, 176, 182
Stahl, Neil, 375
Stanford University, 187, 477–78, 487
Starr, Chris
Raptor, 64
statins, 10, 18
Akira Endo, 82
chemical structures, 350
discovery, 75
health risks, rhabdomyolysis, 107
pricing, 63
Steinberg, Daniel, 95
Stephan, Paula, 315
Sterne, Jean, 262, 274, 277
sterol regulatory element binding process (SREBP), 113
Stockholm, Sweden, 129
stomach ulcers
drug development, 57
streptomycin, 16–17
stroke, 120
sulfadiazine, 277
Sumitomo, 369
sunitinib, 312
Swiss National Science Foundation, 175
Symposium on Drugs Affecting Lipid Metabolism, 6th Annual, 115
Synthalin, 274
T. Rowe Price Group, 394
Tacquini, Alberto C.
renin, 133
Talpaz, Moshe, 352
Tanret, Georges, 272
Tarrytown, New York, 371
tau hyperphosphorylation, 237f. 8.1, 243
tau hypothesis, 242, 244
Taxotere, 379
T-cells
use in cancer treatments, 421
Technivie, 213
Temin, Howard, 342
Nobel Prize 1966, 433
Teva, 369
Textbook of Human Physiology
Robert Tigerstedt, 150
The National Center for Advancing Translational Science (NCATS), 56
The Prescription Drug User Fee Act, 1992 (PDUFA), 54
Tigerstedt, Robert, 129, 146
Lifetime Achievement Award, 130
Textbook of Human Physiology, 150
Tijo, Joh Hin, 337
Titian, 506
TNF (tumor necrosis factor) drugs
pricing, 63
Todaro, George J., 343
Tohoku University Faculty of Agriculture, 82
Index

Tokyo Metropolitan Institute for Neuroscience, 200
Tokyo Noko University, 93
Tokyo, Japan, 85
Trinity College, Dublin
  University Chemical Laboratory, 283
Tübingen, Germany, 228
Tuffier, Theodore, 164
Tufts Medical School, 477
Tufts University, 485
Turina, Marco, 175
Turner syndrome, 337
cause, 308
Twenty First Century Cures Act, US, 503
twin pillars of success
  invention and commercialization, 183
US Catheter and Instrument Company, 167
UK Prospective Diabetes Study
  (1977–1997), 286
Ullrich, Axel, 406
Ungar, Georges, 282
University College Hospital Medical School, London, 266
University Hospital, Zurich, 172
University of Aberdeen, 90
University of Breslau, 274, 282
University of Buenos Aires, 132
University of California, Berkeley, 514
University of California, Los Angeles, 346, 406
University of California, San Diego, 478, 485, 487
University of California, San Francisco, 343, 404, 426, 477–78
University of Catania Medical School, 404
University of Heidelberg, 171
University of Helsinki, 149
University of Lund, Sweden, 287
University of Michigan
  Regional Conference on the
  Basic Mechanisms of Arterial Hypertension, 135
University of Munich, 228
University of Münster, 282
University of Newcastle, England, 230
University of Nottingham, 90
University of Oregon, 168, 170
University of Oregon Medical School, 168
University of Padua, Italy, 506
University of Pennsylvania, 417, 427, 429
University of Pennsylvania Medical School, 338
University of Rochester, 100
University of Strasbourg, 275
University of Texas, 336, 352
University of Texas Southwestern Medical Center, 96
University of Texas Southwestern Medical School, 84
University of Toronto, 275, 516
University of Zurich, 168
US Diabetes Prevention Program, 296
US major causes of death, 2
US standard of living, 1
US Vitamin Corp., New York City, 282
vaccination, 15
Vagelos, P. Roy, 83, 109, 115, 364, 394, 396, 452
Merck & Co., 91
Valenzuela, David, 367
valley of death, 10, 54
van Etten, Richard A., 346
Vane, John, 137, 151, 157
variolation, 15
Varmus, Harold, 343
vascular endothelial growth factor
  (VEGF), 375–76
vascular retinopathy, 120
Vasella, Daniel, 349, 352
vasopressin, 123
Vertex, 68, 205
Vesalius, Andreas, 14
  human anatomy, 505
Veterans Administration Hospital
  Cooperative Study Group on Antihypertensive Agents, 124
Virchow, Rudolf, 334
Volhard, Franz, 151
von Hansemann, Daniel Paul, 335
von Langenbeck, Bernhard, 334
von Leeuwenhoek, Anton, 15
discovery of bacteria, 507
von Mering, Josef, 275
von Recklinghausen, Friedrich Daniel, 305
Waksman, Selman
discovery of streptomycin, 513
streptomycin. See streptomycin
Walker, I.C., 165
Wall Street, 32
Walpole, Horace, 458
serendipity, 458
War on Cancer, 12, 340, 356, 493, 524
Warner-Lambert, 100, 117
Washington University, 92, 165, 364
Washington, DC, 124, 485
Watanabe, C.K., 271, 277
Watson, Thomas, 455
Weber, Max, 464
Weiner, Richard, 404
Weiss, Arthur, 426
Weizmann Institute of Science, Rehovot, Israel, 345, 426
Welch, Arnold, 139, 141, 157
Wellauer, Josef, 172
Werner, Emil, 283
Whitehead, Emma, 417, 432, 445
Wickersham, Peter, 215
Wilde, Oscar, 314
William Cook Europe, 178
Williams, David, 177
Wilson, Jean, 95
Winslow, Ron, 103
Witte, Owen, 345
Witty, Andrew
GlaxoSmithKline, 64

542

Index

Wolfenden, Richard, 142
Woodruff, H. Boyd, 91
Merck, 91
World Health Organization (WHO), 191
100 essential medicines, 398
Anatomical Therapeutic Chemical (ATC) Classification System code, 22, 25
definitions of genetics and genomics, 301
model list of essential medicines, 209
Wren, Sir Christopher, 508
Wyeth, 469

Xeljanz, 67

Yale University, 153, 272
Yamamoto, Akira, 89, 110, 117
Yancopoulos, George, 364
Yellow Emperor’s Classic of Internal Medicine, 127
Zaltrap, 375
Zeitler, Eberhard, 172
Zerhouni, Elias, 395
Zika, 195, 387
Zimmermann, Jurg, 349, 354–55
Zocor (simvastatin), 103, 106–07
Zurich, Switzerland, 172